Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the MAPK Pathway in RAS Mutant Cancers.

Cold Spring Harbor perspectives in medicine - 1 Nov 2018

Hymowitz Sarah G, Malek Shiva

Abstract excerpt

Despite decades of extensive drug discovery efforts, there are currently no targeted therapies approved to treat KRAS mutant cancers. In this review, we highlight the challenges and opportunities in targeting KRAS mutant tumors through inhibition of mitogen-activated protein kinase (MAPK) signaling with conformation-specific kinase inhibitors. Through structural analysis and mechanistic studies with BRAF and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Extracellular Signal-Regulated MAP Kinases
Share to Genes, ras

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to MAP Kinase Kinase Kinases

Share to MAP Kinase Signaling System

Share to Mitogen-Activated Protein Kinases

Share to Proto-Oncogene Proteins B-raf

Share to raf Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 29440321
DOI: 10.1101/cshperspect.a031492
PMCID: PMC6211377

Genes

KRAS
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the MAPK Pathway in RAS Mutant Cancers.PMID 29440321Read ↗

Targeting the MAPK Pathway in KRAS-Driven Tumors.Semantic proximity Read ↗

Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.Semantic proximity Read ↗

Targeting mutant KRAS.Semantic proximity Read ↗

Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers.Semantic proximity Read ↗

The current state of the art and future trends in RAS-targeted cancer therapies.Semantic proximity Read ↗

Not just gRASping at flaws: finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers.Semantic proximity Read ↗

Inhibitors of the ERK mitogen-activated protein kinase cascade for targeting RAS mutant cancers.Semantic proximity Read ↗

Targeting KRAS in Cancer: Promising Therapeutic StrategiesSemantic proximity Read ↗

Past, Present, and Future of Targeting Ras for Cancer Therapies.Semantic proximity Read ↗

Strategies for Targeting KRAS: A Challenging Drug Target.Semantic proximity Read ↗

KRAS Mutations in Cancer: From Molecular Insights to Therapeutic Strategies.Semantic proximity Read ↗

Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.